Keywords: Ipsen, Salk Institute, Gustave Roussy Institute, Degenerative diseases, Cancer treatment

Ipsen renews research accord with Salk Institute and partners with Gustave Roussy

Article | 12 July 2011

Print This

French drugmaker Ipsen (Euronext: IPN) and the Salk Institute for Biological Studies are renewing the Ipsen Life Sciences Program at ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in